NASDAQ:LNSR LENSAR (LNSR) Stock Price, News & Analysis $14.03 +0.12 (+0.86%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$14.02 0.00 (-0.04%) As of 04:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About LENSAR Stock (NASDAQ:LNSR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get LENSAR alerts:Sign Up Key Stats Today's Range$13.97▼$14.2650-Day Range$9.29▼$16.8752-Week Range$2.95▼$17.31Volume223,556 shsAverage Volume71,521 shsMarket Capitalization$165.40 millionP/E RatioN/ADividend YieldN/APrice Target$15.00Consensus RatingHold Company OverviewLENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.Read More… LENSAR Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks14th Percentile Overall ScoreLNSR MarketRank™: LENSAR scored higher than 14% of companies evaluated by MarketBeat, and ranked 829th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingHold Consensus RatingLENSAR has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageLENSAR has only been the subject of 2 research reports in the past 90 days.Read more about LENSAR's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of LENSAR is -9.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of LENSAR is -9.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLENSAR has a P/B Ratio of 4.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about LENSAR's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.29% of the float of LENSAR has been sold short.Short Interest Ratio / Days to CoverLENSAR has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in LENSAR has recently increased by 92.88%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLENSAR does not currently pay a dividend.Dividend GrowthLENSAR does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.29% of the float of LENSAR has been sold short.Short Interest Ratio / Days to CoverLENSAR has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in LENSAR has recently increased by 92.88%, indicating that investor sentiment is decreasing significantly. News and Social Media2.1 / 5News Sentiment0.83 News SentimentLENSAR has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for LENSAR this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for LNSR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, LENSAR insiders have not sold or bought any company stock.Percentage Held by Insiders38.52% of the stock of LENSAR is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions40.15% of the stock of LENSAR is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about LENSAR's insider trading history. Receive LNSR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LENSAR and its competitors with MarketBeat's FREE daily newsletter. Email Address LNSR Stock News HeadlinesIs LENSAR (LNSR) a Deeply Undervalued Stock?April 10, 2025 | msn.comLENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSRMarch 26, 2025 | businesswire.comTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.April 29, 2025 | American Alternative (Ad)Lensar downgraded to Hold from Buy at Lake StreetMarch 26, 2025 | markets.businessinsider.comLake Street Downgrades LENSAR (LNSR)March 25, 2025 | msn.comShareholder Alert: The Ademi Firm Investigates Whether LENSAR, Inc. is Obtaining a Fair Price for Its Public ShareholdersMarch 24, 2025 | tmcnet.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating LENSAR, Inc. BuyoutMarch 24, 2025 | markets.businessinsider.comLake Street Reaffirms Their Buy Rating on LENSAR (LNSR)March 24, 2025 | markets.businessinsider.comSee More Headlines LNSR Stock Analysis - Frequently Asked Questions How have LNSR shares performed this year? LENSAR's stock was trading at $8.94 on January 1st, 2025. Since then, LNSR stock has increased by 56.9% and is now trading at $14.03. View the best growth stocks for 2025 here. How were LENSAR's earnings last quarter? LENSAR, Inc. (NASDAQ:LNSR) announced its quarterly earnings data on Thursday, February, 27th. The company reported ($1.61) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by $1.40. The firm earned $16.73 million during the quarter, compared to analyst estimates of $14.95 million. LENSAR had a negative trailing twelve-month return on equity of 49.02% and a negative net margin of 34.03%. Read the conference call transcript. How do I buy shares of LENSAR? Shares of LNSR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of LENSAR own? Based on aggregate information from My MarketBeat watchlists, some other companies that LENSAR investors own include Arch Capital Group (ACGL), Aprea Therapeutics (APRE), Artelo Biosciences (ARTL), AstraZeneca (AZN), Baidu (BIDU), Cidara Therapeutics (CDTX) and The Carlyle Group (CG). Company Calendar Last Earnings2/27/2025Today4/29/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:LNSR CIK1320350 Webwww.lensar.com Phone888-536-7271FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$15.00 Low Stock Price Target$15.00 Potential Upside/Downside+6.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,380,000.00 Net Margins-34.03% Pretax Margin-34.03% Return on Equity-49.02% Return on Assets-21.12% Debt Debt-to-Equity RatioN/A Current Ratio3.37 Quick Ratio2.10 Sales & Book Value Annual Sales$53.49 million Price / Sales3.09 Cash FlowN/A Price / Cash FlowN/A Book Value$2.97 per share Price / Book4.72Miscellaneous Outstanding Shares11,789,000Free Float7,141,000Market Cap$165.40 million OptionableOptionable Beta0.56 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:LNSR) was last updated on 4/29/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENSAR, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENSAR With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.